首页> 外文OA文献 >DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all- retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

【2h】

DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all- retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy

机译：决定因素：对于60岁以上的急性髓细胞性白血病患者，单独或与组蛋白脱乙酰酶抑制剂丙戊酸（VPA）和全视黄酸（ATRA）联合使用的低剂量地西他滨（DAC）的前瞻性随机多中心II期临床研究不适合诱导化疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all- trans retinoic acid (ATRA) in patients >60?years with acute myeloid leukemia who are ineligible for induction chemotherapy [J] . Olga Grishina, Claudia Schmoor, Konstanze D?hner, BMC Cancer . 2015,第1期

机译：结论：对于≥60岁的急性髓细胞性白血病患者，单独或与组蛋白脱乙酰酶抑制剂丙戊酸（VPA）和全反式维甲酸（ATRA）联合应用低剂量地西他滨（DAC）的前瞻性随机多中心II期临床研究不适合进行诱导化疗的人
2. Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients [J] . Lubbert Michael, Grishina Olga, Schmoor Claudia, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：在新诊断的老年人非适应性AML中比较有或没有丙戊酸（VPA）和有或没有全反式维甲酸（ATRA）的地西他滨（DAC）的随机II期研究决策者（AMLSG 14-09）的结果耐心
3. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 x 2, Phase II Trial [J] . Luebbert Michael, Grishina Olga, Schmoor Claudia, Journal of Clinical Oncology . 2020,第3期

机译：VALPROATE和RETICICICAN与急性髓性白血病的老年人非特征患者联合联合甲酸：多中心，随机，2 x 2，II期试验的结果
4. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients 60 years with acute myeloid leukemia who are ineligible for induction chemotherapy [O] . Olga Grishina, Claudia Schmoor, Konstanze Döhner, 2015

机译：决策：低剂量地西他滨（DAC）单独或与组蛋白脱乙酰基酶抑制剂丙戊酸（VPA）和全反式维甲酸（ATRA）联合给药于60岁以上的急性髓细胞性白血病患者的前瞻性随机多中心II期试验没有资格进行诱导化疗
5. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia [O] . Andrea Kuendgen, Mathias Schmid, Richard Schlenk, 2006

机译：组蛋白脱乙酰酶（HDAC）抑制剂丙戊酸作为单疗法或与急性髓性白血病患者的全反式视黄酸组合

著录项

引文网络

相似文献

相关主题

期刊订阅